While Amgen and others in the industry are lowering drug prices, J&J decided it was in their best interest to raise prices on 12 drugs today.
Most of the J&J increases were between 6 percent and 7 percent and the increases will come from the psoriasis treatment Stelara, prostate cancer drug Zytiga and blood thinner Xarelto,
J&J said the average list price increase on its drugs will be 4.2 percent this year. However, it expects the net price it actually receives for its medicines to drop. That is because drugmakers negotiate rebates and discounts off the list price with payers in order to ensure patient access to their products.
I feel like Gorsky can't help himself and being in the news for all the wrong reasons.